Evidence map›Paper›PMID 40787474›Full record

ArticleRare tumors2025

Efficacy and cardiac safety of aldoxorubicin in metastatic solitary fibrous tumour.

Karolina Vosylius, Gareth Price, Andrea Napolitano, Charlotte Benson, Nicos Fotiadis, Khin Thway, Ka Hou Christien Li, Robin L Jones

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Rare tumors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Karolina VosyliusSarcoma Trials Unit, Royal Marsden NHS Foundation Trust, London, UK.
Gareth PriceSarcoma Trials Unit, Royal Marsden NHS Foundation Trust, London, UK.ORCID https://orcid.org/0009-0000-9462-6474
Andrea NapolitanoSarcoma Trials Unit, Royal Marsden NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0002-7509-1555
Charlotte BensonSarcoma Trials Unit, Royal Marsden NHS Foundation Trust, London, UK.
Nicos FotiadisSarcoma Trials Unit, Royal Marsden NHS Foundation Trust, London, UK.
Khin ThwaySarcoma Trials Unit, Royal Marsden NHS Foundation Trust, London, UK.
Ka Hou Christien LiSarcoma Trials Unit, Royal Marsden NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0001-8305-3850
Robin L JonesSarcoma Trials Unit, Royal Marsden NHS Foundation Trust, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Solitary fibrous tumours (SFT) are very rare mesenchymal neoplasms. While surgery remains a standard treatment for localised disease, effective and long term treatment options for metastatic disease are lacking, making the use of aldoxorubicin a novel and promising systemic treatment in SFTs. We present a 30-year-old male who underwent surgical resection for a solitary fibrous tumour of the right leg. Postoperative imaging revealed metastatic disease in the liver and left upper quadrant. He was initially treated with pazopanib but experienced disease progression after 24 weeks. The patient was then enrolled on a phase III trial evaluating aldoxorubicin for advanced soft tissue sarcomas and received 350 mg/m

Indexed as

aldoxorubicinanthracycline prodrugsoft tissue sarcomassolitary fibrous tumours (SFT)

Identifiers

PMID40787474
PMCPMC12332252

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.